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Abstract
aspergilli, less susceptible to antifungals emerge and
resistance  to  azoles  have  been  found  mainly  in  As-
pergillus fumigatus; this has launched a new phase in
handling aspergillosis. Resistant strains have currently
been  reported  from  Belgium,  canada,  china,  den-
mark,  france,  norway,  spain,  sweden,  the  nether-
lands, uK and the usa. centres in the uK (Manches-
ter) and the netherlands (nijmegen) have described
particularly high frequencies (15 and 10% respective-
ly), and a significant increase in azole resistance in re-
cent years. the reason of this high incidence may be
due to long term azole therapy in patients with chron-
ic aspergillosis in Manchester, and due to high use of
agricultural azoles in nijmegen. the primary underly-
ing  mechanism  of  resistance  is  as  a  result  of  alter-
ations in the cyp51A target gene, with a variety of mu-
tations  found  in  clinical  isolates  and  one  genotype
identified  in  the  environmental  (lH98).  Reports  on
well  documented  in  vitro  and  in  vivo  resistance  to
echinocandins are rare for Aspergillus species and re-
sistance may be under-diagnosed as susceptibility test-
ing is less frequently performed due to technical rea-
sons.
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IntRoductIon
Invasive fungal infections (Ifd) are increasingly rec-
ognized and represent a primary cause of morbidity
and mortality in critically ill patients [1-4]. a variety of
factors,  including  immunosuppressive  agents,  broad-
spectrum antibiotics, and antineoplastic agents influ-
ence the incidence and severity of Ifds [1]. trans-
plant and haematopoietic stem cell transplant recipi-
ents, intensive care unit and surgical patients display
the population at risk [1, 4-7]. Aspergillus species have
become the most important pathogens [8]. the intro-
duction of voriconazole, posaconazole and echinocan-
dins (caspofungin, micafungin and anidulafungin) im-
proved the therapeutic option for treatment of inva-
sive aspergillosis (Ia) [9]. although the outcome of Ia
is largely influenced by the state of immunosuppres-
sion, factors related to the fungus also play a role. un-
til  recently,  species  identification  was  sufficient  to
guide  antifungal  therapy,  but  the  emergence  of  ac-
quired resistance limits the use of species identifica-
tion for predicting activity of antifungal agents. as-
pergilli, less susceptible to antifungals emerged and ac-
quired resistance to azoles have been found mainly in
Aspergillus fumigatus [10]; this has launched a new era
in handling aspergillosis. this article reviews the epi-
demiology and antifungal resistance against azoles and
candins  with  particular  emphasis  on  Aspergillus
species.
EPIdEMIology of InvasIvE asPERgIllosIs
In a 4-year-study Pagano et al. [11] showed that 64%
of Ifds in patients with haematological malignancies
were caused by moulds and among them 90% were
due to Aspergillus species. overall, the incidence of
Ia varies according to underlying diseases, pathogen
[lf] and geographic location [10, 12, 13]; rates of up to
7% are reported in Europe [11].  Mortality rates for Ia
are  high  and  vary  according  to  patient  population,
ranging from 38% in patients with acute myelogenous
leukaemia, from 50-60% in patients with organ trans-
plantation  and  from  70-85%  in  other  immunosup-
pressed patients [11-16].    
although A.  fumigatus still represents the leading
cause of Ia, species like Aspergillus terreus and As-
pergillus flavus become more frequent [15, 17]. these
non-A. fumigatus may be intrinsically resistant to anti-
fungal agents (eg A. ustus) [18] and the clinical pre-
sentation and evolution of Ia may differ from com-
monly observed A. fumigatus infections [18-23]. Maxi-
mizing the efforts to culture the causative pathogen
appears necessary to allow identification and suscepti-
bility testing. 
EPIdEMIology of azolE and candInE
REsIstancE In clInIcal A. fumigAtus
antifungal drug resistance is normally quantified using
the  minimum  inhibitory  concentration  (MIc).  the
MIc represents the lowest drug concentration that re-
sults in a notably reduction or complete lack of fungal
growth. In vitro resistance can be primary (intrinsic)
or  secondary  (acquired).  Primary  resistance  occurs
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3) Lass-Flörl_Umbruchvorlage  23.03.11  12:31  Seite 153naturally,  without  prior  exposure  to  the  drug.  sec-
ondary resistance is generated following exposure to
an antifungal and may be associated with an altered
gene expression [10, 24]. clinical resistance is defined
as the failure to eradicate an infection despite the ad-
ministration of an adequate antifungal [24]. such fail-
ures can be attributed to a combination of the host,
the pathogen and the drug [24]. 
using the European committee for antibiotic sus-
ceptibility  testing  (Eucast)  methodology  break-
points were recently proposed for A.  fumigatus and
itraconazole, voriconazole and posaconazole [25]; for
itraconazole and voriconazole, <2 mg/l (susceptible),
2 mg/l (intermediate) and >2 mg/l (resistant); for
posaconazole, <0.25, 0.5 and >0.5 mg/l respectively.
It  is  suggested  to  differentiate  between  single-azole,
pan-azole and multi-azole resistance (see table 1), the
majority of infections is associated with clinical failure
when treated with the ascertained agent [26]. 
It  was  thought  that  acquired  resistance  of  As-
pergillus species to triazoles is unfrequently [27, 28].
yet reports from the netherlands and Manchester dis-
play an alarming increase of azole resistance in A. fu-
migatus since  1998  [26,  29,  30].  the  first  published
case  of  itraconazole-resistance  in  A.  fumigatus ap-
peared in 1997 [31]; in 2000, a survey testing over 900
isolates showed a 2% prevalence of Itc resistance in
Manchester [32]. In 2007 the percentage of patients
with an azole-resistant A.  fumigatus increased up to
15% [25, 26]. In the netherlands azole resistance in-
creased dramatically from 2.5% in 2000, to 4.9% in
2002, to 6.6% in 2004 and to 10% in 2009 [25]. this
represents an increasing frequency of 6% per year and
is an issue due to the limited number of antifungals.
overall, azole-resistance differs from country to coun-
try  and  occurred  sporadically  in  Belgium,  denmark,
france, sweden, spain and norway [33-39]. In spain,
the prevalence is about 2% among clinical A. fumiga-
tus and in austria about 0%. In the usa, species with
MIcs of voriconazole and posaconazole > 2 mg/l re-
main rare, less than 1% [27]. 
the clinical presentation and disease evolution may
be related to the underlying genotypes in A. fumigatus
(table 2).  Isolates have been collected from patients
suffering from chronic aspergillosis [29] and invasive
diseases [26, 33].    
azole drug resistance in A. fumigatus has been re-
ported both, before and after drug exposure; acquired
resistance  appears  to  develop  through  treatment  of
patients  or  through  exposure  of  isolates  to  azole
fungicides in the environment [40]. 
these findings have major implications for clinical
practice especially as fungal drug resistance is an acute
issue due to the limited number of antifungal com-
pounds.  alternative  strategies  utilising  combination
therapy will become more attractive. Experts expect
that triazole resistance in this haploid, sparingly sexual
worldwide airborne fungus will increase [8]. Key ele-
ments in the management of patients will be an accu-
rate speciation of Aspergillus species and the perfor-
mance of in vitro susceptibility testing for an approbi-
ate antifungal treatment. Presently we do not have ex-
act  data  on  the  prevalence  of  azole-resistance  as-
pergilli in germany, but seems to be rather low than
high. anyway, a shift has occurred in the epidemiology
of invasive infections in Europe [8]. where invasive
candidiasis was once the predominant type of invasive
fungal infections, invasive mould infections have be-
come  increasingly  important,  including  those  caused
by unusual pathogens. Moulds have become the lead-
ing  cause  of  Ifd  in  some  populations.  Aspergillus
species are the most frequent mould pathogens, but
the  number  of  infections  caused  by  previously  rare
pathogens,  such  as  the  zygomycetes  and  fusarium
species, is increasing. the reasons for the shift in the
epidemiology  are  multifactorial,  but  are  a  result,  at
least  in  part,  of  the  increased  use  of  extensive
voriconazole and echinocandins as prophylaxis/treat-
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table 1. azole resistance in A. fumigatus.
Phenotypes description
Pan-azole resistant  MIcs are in the resistant range for all available active azoles
Multi azole resistance MIcs are in the resistant range for more than one, but not all azoles
Itraconazole, voriconazole or posaconazole resistant MIcs are in the resistant range for a single azole
MIcs= minimal inhibitory concentrations
table 2. clinical overview of azole resistance in A. fumigatus.
location clinical presentation Epidemiology Pathomechanism
nijmegen Invasive pulmonary aspergillosis Mainly azole naive dominant resistance 
cns aspergillosis  Previous azole  mechanism: 
osteomyelitis exposure tR/l98H
Manchester chronic aspergillosis Previous azole  Multiple resistance
aspergilloma exposure mechanisms:
aBPa g448s, M220, P216l,
cns aspergillosis tR/l98H
aBPa=allergic bronchopulmonary aspergillosis
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suppressed patients with risk factors, the patient popu-
lations  for  Ia  will  expand  and  will  include  patients
with  haematological  malignancy,  Icu  intervention,
pulmonary disease [e.g.chronic obstructive pulmonary
disease (coPd) and asthma], sot recipients and pa-
tients with solid tumours. 
Much less is currently known about echinocandin
resistance in Aspergillus, in part because susceptibility
testing  is  not  routinely  performed  and  because  the
methods suffer from technical difficulties and subopti-
mal  reproducibility  [41,  42];  breakthrough  infections
with  A.  fumigatus showing  high  minimum  effective
concentrations  have  been  reported  sporadically  [43].
so far, the selection pressure of candins has risen and
the development of resistance is presumed to be in-
evitable. 
MEcHanIsM of azolE-REsIstancE In
A. fumigAtus
the triazoles block the ergosterol biosynthetic path-
way at the c14-α-demethylation stage [44]. these anti-
fungals  bind  to  lanosterol  14-α-demethylase  (14-α-
dM,  or  Cyp51p)  which  is  encoded  by  the  Erg11
genes. such step leads to depletion of ergosterol and
an accumulation of lanosterol and other toxic 14-α-
methylated sterols. 
several  pathomechanisms  account  for  azole  resis-
tance in A. fumigatus; these include a modification of
target enzymes, an increased expression of drug efflux
mechanisms, an overexpression of target enzymes, an
incorporation  of  exogenous  cholesterol,  an  overex-
pression  of  HsP90  and  of  a  sterole-regulatory  ele-
ment binding protein [45, 46]. the resistance pheno-
type depends on the amino-acid substitution and more
than one azole can be affected. azole-resistant isolates
have been reported as multidrug resistant [47], multi-
azole resistant [48], azole cross-resistant [27] and mul-
tiple-triazole resistant [26, 33] isolates. In most cases
azole resistance has been associated with point muta-
tions in cyp51A, which represents the target enzyme
of the azoles [25]; hot spots at codons 54, 98 and 220
are most frequently characterized [26, 33, 35, 48-50].
Interestingly,  other  mutations  have  been  found  in
azole susceptible strains and so are unlikely to be asso-
ciated with resistance [51].  
the resistance mechanisms differ between the dutch
and British azole-resistant isolates; in the netherlands,
the presence of a single resistance mechanism (denot-
ed by tR/l98H, a point mutation at codon 98 accom-
panied by a tandem repeat in the promoter region), was
found in over 90% of clinical A. fumigatus isolates. By
contrast, several CYP51A mutations are present in the
uK strains [25, 33] and no prevalence of any one alter-
ation. the reasons for this might be due to differences
in the patient population from which the isolates origi-
nate  [25].  for  the  dutch  isolates,  an  environmental
source is very likely. azole-resistance may develop due
to exposure of A.  fumigatus to azole fungicides for
plant protection [30, 33]. Howard et al. suggest that the
reasons of the widespread increase of azole-resistance
in the uK may be part of long-term azole drug expo-
sures in patients [29].
MEcHanIsM of EcHInocandIn-REsIstancE
In AsPErgillus sPEzIEs
the β-(1,3)-d-glucan is an integral part of the fungal
cell wall. Echinocandins are a unique class which block
the β-(1,3)-d-glucan synthesis by inhibiting β-(1,3)-d-
glucan synthase [52]. this process leads to abnormal
hyphal growth in moulds [24]. Much less is currently
known  about  echinocandin  resistance  in  Aspergillus
and only few clinical isolates associated with treatment
failures have been investigated. In such isolate muta-
tion in the fKs1 target gene was not detected, but ex-
pression of the fKs1 gene was found to be upregulat-
ed  [37].  Manipulated  or  laboratory-selected  strains
with various degrees of caspofungin resistance have
been described [42, 53, 54]. some of these strains have
been  found  to  have  mutations  in  the  EcM33  gene
(AfuEcm33), encoding cell wall proteins. strains with
mutations in the fKs1 gene encoding a subunit of the
￟ -1,3-d-glucan synthase enzyme have been generated
[42].  In  other  resistant  Aspergillus mutants  the  glucan
synthase  exhibited  a  wild-type  AffKs1 gene  se-
quence, where the function, level, and the enzyme it-
self were susceptible to caspofungin [42, 45].
differences in the susceptibility to the echinocan-
dins exist among the Aspergillus spezies. for example,
Aspergillus niger is much more susceptible to echino  -
candins than other species probably in charge of its
different cell-wall composition [55]. Aspergillus lentu-
lus isolates  are  less  susceptible  to  caspofungin,  al-
though  they  maintain  susceptibility  to  anidulafungin
and micafungin. the analysis of the a. lentulus fks se-
quence did not reveal a polymorphism at any of the
known hot-spot regions of the gene [56]. 
cRoss REsIstancE aMong azolEs and
EcHInocandIns
cross-resistance  patterns  are  closely  linked  with  the
position of the mutation in the cyp51A gene [29, 57].
Isolates with alterations at eg codons 98 demonstrate a
pan-azole  resistance  phenotype.  Isolates  with  muta-
tions at codon 54 remain voriconazole susceptible al-
though cross-resistant to posaconazole. 
cross-resistance patterns in isolates with M220 al-
terations appear to be unpredictable, particularly with
respect to voriconazole. the risk of cross-resistance
between the azole compounds is high, in one report
74% and 65% of itraconazole resistant isolates were
cross-resistant  to  posaconazole  and  voriconazole  re-
spectively [29].
Between itraconazole, voriconazole and ravucona-
zole cross-resistance was demonstrated in 10 clinical
isolates of A. fumigatus obtained from patients with
long-term  exposure  to  itraconazole  or  voriconazole
[50]. also, broad-spectrum cross-resistance among all
the azoles has been shown in A. fumigatus in a patient
receiving  prolonged  itraconazole  prophylaxis  [47].
overall, there is a limited number of reported cases
that help us to understand the clinical impact of azole
resistance on clinical outcome. for example, in a small
case  series  of  patients  with  Ia  and  no  respond  to
voriconazole,  treatment  with  posaconazole  was  suc-
cessful in 50% of infections [58]. on the other hand
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tant A. fumigatus strain, posaconazole, which is struc-
turally similar to itraconazole, was active in high doses
[59].
the potential frequencyof cross-resistance amongst
echinocandins in Aspergillus species is still unclear and
has  not  been  investigated  in  detail  [60].  at  present,
there is no evidence that the activity and efficacy of
other antifungal compounds, such as the polyenes and
echinocandins, is attenuated in azole-resistant isolates
[26, 33]. 
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